

Design, Synthesis, and Pharmacological Evaluation of Monocyclic Pyrimidinones as Novel Inhibitors of PDE5

Guan Wang, Zheng Liu, Tiantian Chen, Zhen Wang, Huaiyu Yang, Mingyue Zheng, Jing Ren, Guanghui Tian, Xiaojun Yang, Li Li, Jianfeng Li, Jin Suo, Rongxia Zhang, Xiang-Rui Jiang, Nicholas Kenneth Terrett, Jing-Shan Shen, Yechun Xu, and Hualiang Jiang

J. Med. Chem., **Just Accepted Manuscript** • Publication Date (Web): 08 Nov 2012

Downloaded from <http://pubs.acs.org> on November 17, 2012

Just Accepted

"Just Accepted" manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides "Just Accepted" as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. "Just Accepted" manuscripts appear in full in PDF format accompanied by an HTML abstract. "Just Accepted" manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). "Just Accepted" is an optional service offered to authors. Therefore, the "Just Accepted" Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the "Just Accepted" Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these "Just Accepted" manuscripts.



ACS Publications
High quality. High impact.

Design, Synthesis, and Pharmacological Evaluation of Monocyclic Pyrimidinones as Novel Inhibitors of PDE5

Guan Wang,^{†,‡} Zheng Liu,^{§,‡} Tiantian Chen,^{†,‡} Zhen Wang,[†] Huaiyu Yang,[†] Mingyue, Zheng,[†] Jing Ren,[†] Guanghui Tian,[§] Xiaojun Yang,[§] Li Li,[†] Jianfeng Li,[†] Jin Suo,[†] Rongxia Zhang,[†] Xiangrui Jiang,[†] Nicholas Kenneth Terrett,[§] Jingshan Shen,^{*,†} Yechun Xu,^{*,†} and Hualiang Jiang^{*,†}

[†] CAS Key Laboratory for Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, China

[§] Vitargeta Therapeutics Inc. Plainsboro, NJ 08536, USA.

ABSTRACT

Cyclic nucleotide phosphodiesterase type 5 (PDE5) is a prime drug target for treating the diseases associated with a lower level of the cyclic guanosine monophosphate (cGMP), which is a specific substrate for PDE5 hydrolysis. Here we report a series of novel PDE5 inhibitors with the new scaffold of monocyclic pyrimidin-4(3H)-one ring developed using the structure-based discovery strategy. In total, 37 derivatives of the pyrimidin-4(3H)-ones, were designed, synthesized, and evaluated for

their inhibitory activities to PDE5, resulting in 25 compounds with IC_{50} ranging from 1 to 100 nM and 11 compounds with IC_{50} ranging from 1 to 10 nM. Compound **5**, 5,6-diethyl-2-[2-n-propoxy-5-(4-methyl-1-piperazinylsulfonyl)phenyl]pyrimidin-4(3H)-one, the most potent compound, has an excellent IC_{50} (1.6 nM) in vitro and a good efficacy in a rat model of erection. It thus provides a potential candidate for the further development into a new drug targeting PDE5.

INTRODUCTION

Cyclic nucleotide phosphodiesterase type 5 (PDE5), mostly distributed in smooth muscle and found in corpus cavernosum, heart, lung, platelets, prostate, urethra, bladder, liver, brain, and stomach,¹⁻⁴ is responsible for specifically cleaving the second messenger, cyclic guanosine monophosphate (cGMP).⁵ Inhibitors of PDE5 prevent the hydrolysis of cGMP, leading to their potential to treat the diseases associated with low cGMP levels.⁶ PDE5 is thus a prime target for the development of inhibitors which have served as drugs in the treatment of male erectile dysfunction (ED) and cardiovascular diseases. For example, sildenafil, the prototypical member of the PDE5 inhibitors, was approved by FDA in 1998 as the first oral medicine for the treatment of ED,⁷ and was also launched for the treatment of pulmonary arterial hypertension (PAH) in

2005.^{6, 8-10} Two other agents, vardenafil and tadalafil, are also used to treat ED and PAH.^{4, 11} Moreover, tadalafil has received the FDA approval for the treatment of lower urinary tract symptoms (LUTS) in men with benign prostatic hyperplasia (BPH). Another inhibitor, avanafil, as a second generation PDE5 inhibitor, was also approved for the treatment of ED. Despite deficiencies with these inhibitors,¹²⁻¹⁵ such as the lack of sufficient selectivity against other PDE isozymes, most notably PDE6 or PDE11,¹⁶ it has been proved that the inhibition of PDE5 is an effective therapy for the diseases mentioned above and there is continuing interest in discovering novel PDE5 inhibitors. Additionally, the medical application of PDE5 inhibitors for other diseases such as stroke, Raynaud's disease, overactive bladder, and premature ejaculation has also been indicated.^{2, 17}

The solved crystal structures of the PDE5 catalytic domain in complex with different inhibitors have revealed the characteristic binding interactions of inhibitors with the enzyme. These include mono or bidentate hydrogen bonds (H-bonds) between inhibitors and the residue Q817, hydrophobic interactions, in particular the π - π stacking interactions between the aromatic rings of inhibitors and the hydrophobic clamp mainly composed of residues V782 and F820, and occasionally interactions also formed between inhibitors and two metal ions (Zn^{2+} and Mg^{2+} in most cases) coordinated at the active site of the catalytic

domain^{9, 18-21}. For example, in the crystal structure of PDE5/sildenafil (pdb codes 1UDT and 2H42), bidentate H-bonds are formed between the amide moiety of the pyrazolopyrimidinone of sildenafil and the side-chain of Q817. A third H-bond is formed between the N2 atom of the pyrazol ring and a water molecule that simultaneously forms H-bonds with the side-chain of Y612, the main-chain of D764, and a water molecule coordinating to Zn²⁺ (Figure 1A). The pyrazole ring as well as the ethoxyphenyl group of sildenafil also interact with residues V782, L785, Y612, F820, F786, A783, and L804, in particular, including a face-to-face π - π stacking interaction with the phenyl ring of F820^{19, 21}. All these available crystal structures associated with the pharmacological data enable us to carry out structure-based discovery or design of more potent and pharmacologically favorable inhibitors of PDE5.

We previously designed and synthesized a series of quinazolin-4(3H)-ones by introducing the phenyl ring influenced by the structure of sophoflavescenol instead of the pyrazol ring in sildenafil so as to improve the hydrophobic interactions with the residues of PDE5 and reduce or cancel the interactions of the inhibitor with the metal ions. This finally resulted in inhibitors of PDE5 such as compound **1** (Scheme 1) with similar potency to sildenafil but improved selectivity of PDE5 over PDE6.²² In order to reduce the size of the compound but still keep its the hydrophobic interactions with the enzyme, we designed and synthesized

compound **2**, bearing a fused cyclopentene ring instead of the sophoflavescenol-derived substituted phenyl ring in compound **1**. However, it turns out that compound **2** displayed a dramatic loss in PDE5 affinity: only 24% inhibition at 1 μ M compound concentration. We determined the crystal structure of PDE5 in complex with compound **2** and superimposed it to the structure of PDE5/sildenafil. As we can see from the superimposition of compound **2** and sildenafil in Figure 1B, the scaffold of compound **2** is similar to sildenafil but it is much simplified around the bicyclic rings. Because of its hydrophobic character, the cyclopentene ring in compound **2** binds to the sub-pocket (SP1) created primarily by residues L765, I768, and F820, resulting a shift of the whole compound, thus breaking its perfect π - π stacking interactions with F820 compared to the binding of sildenafil (Figures 1B, 1C and 2B). However, it is surprising to see that the water molecule which forms H-bonds with both residues (Y612 and D764) and the water molecule coordinating to Zn^{2+} also appear in the complex structure of PDE5/**2**, although there is no H-bond formed between the compound **2** and the water molecule (Figure 1B). We also find this water molecule in the apo structure of PDE5 (pdb code 2H40) and five other crystal structures of PDE5 in complex with the inhibitors which have a similar scaffold structure and binding position as the pyrazolopyrimidinone of sildenafil. These structures are PDE5 in complex with sildenafil (pdb code 1UDT and 2H42), IBMX (pdb code

1
2
3 1RKP),
4
5
6 5-ethoxy-4-(1-methyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo[4,3-d]pyr
7
8
9 imidin-5-yl)thiophene-2-sulfonamide (pdb code 3BJC), and vardenafil
10
11 (pdb code 3B2R) (Figure 1C). The resolution of these five selected
12
13 complex structures is all above 2.5 angstroms in order to see the key
14
15 water molecules that H-bond with the inhibitors as well as Y612 and
16
17 D764. It is notable that a water molecule is always present in the
18
19 structures, and that the hydrophobic substituents on the pyrazol, pyrrole
20
21 or other heterocyclic ring occupy the same sub-pockets SP1 and SP2
22
23 (Figure 1C). This indicates that the binding of the water molecule to the
24
25 enzyme is strong and acts essentially as a residue of the enzyme.
26
27
28
29
30
31 H-bonding of the polar atom in the inhibitor with this water molecule
32
33 increases its binding affinity to the enzyme. Meanwhile, the hydrophobic
34
35 substituents on the heterocyclic ring interact with the two sub-pockets
36
37 nearby. Accordingly, the hydrophobic cyclopentene ring of compound **2**
38
39 has to bind into the sub-pocket SP1 so as to avoid a close contact with
40
41 this water molecule.
42
43
44
45

46 These structural insights inspired us to design and synthesize
47
48 compound **3**, opening the cyclopentene ring and retaining only a planar
49
50 monocyclic structure in the compound so as to enable the two
51
52 hydrophobic substituent groups on the pyrimidin-4(3H)-one ring to fit
53
54 into the two sub-pockets SP1 and SP2. Fortunately, compound **3**
55
56
57
58
59
60

exhibited a significant increase in the potency to PDE5 compared to that of compound **2**. After that, we designed and synthesized a series of substituted pyrimidones represented by a general structure of **4** to systematically study the monocyclic pyrimidones as inhibitors of PDE5. Among these compounds, compound **5** has an excellent IC_{50} (1.6 nM), good selectivity (29-fold) over PDE6 in vitro and good efficacy in a rat model of erection. The binding position of compound **5** in its crystal structure with PDE5 is superimposed well on that of sildenafil as shown in Figure 1D, which proved that the ring opening could fully overcome the disadvantages of the cyclopentene ring in compound **2**, shift the whole compound back to the same binding location as sildenafil, and thus recover or even improve the potency of the compound against PDE5. Accordingly, our study not only obtained more potent inhibitors of PDE5 but also provided a novel scaffold for further selectivity and metabolism optimization of PDE5 inhibitors. This study therefore presents a good example of the structure-based discovery of potent PDE5 inhibitor.

1. CHEMISTRY

We describe herein the synthesis of novel inhibitors of PDE5 bearing a monocyclic pyrimidinone core. To gain a rapid exploration of SAR, two different synthetic routes for bulk preparation of two series of designed derivatives were applied. The synthetic approach to obtain 2-phenylpyrimidin-4(3H)-ones **2**, **3**, **5**, and **9-31** is outlined in Scheme 2.

Compound **7**, 2-Propoxy-5-(4-methylpiperazin-1-yl) sulphonylbenzamidine, is the key intermediate, and the synthesis of this compound was reported previously.²³ The reaction of **7** with diethyl malonate, ethyl cyanoacetate, and the appropriate β -ketoesters **8**, which were either commercially available or prepared by the procedure described in the literature,²⁴ in DMF with the presence of anhydrous potassium carbonate at 100°C to obtain substituted pyrimidin-4(3H)-ones. In addition, compound **9** was acetylated using acetic anhydride to yield compound **11**, and halogenation of compounds **13** and **15** resulted in compounds **21-26**.

The effect of the different substituent at the 2'-position of the phenyl ring of pyrimidin-4(3H)-ones was investigated by synthesizing compounds **36-39** using an alternative route outlined in scheme 3. The intermediates, compounds **34**, prepared in the manner described in Scheme 2, was halogenated, then treated with chlorosulfonic acid, and finally followed by N-methyl piperazine, resulting in the compounds **36-39**.

2. RESULTS AND DISCUSSION

3.1 Structure determination of compounds **2** and **5** in complex with the PDE5 catalytic domain

The crystal structures of compounds **2** and **5** in complex with the catalytic domain of PDE5 have been determined by soaking the

compounds into the apo PDE5 crystals (space group, $P3_121$), which diffracted to 2.4, and 2.28 angstroms, respectively (Table S1). The ($F_o - F_c$) difference electron-density maps contoured at 3.0 σ for compounds **2** and **5** in two crystal structures were shown in Figure S1. Similar to the binding of sildenafil with PDE5, both compounds fitted into the substrate binding pocket located in the centre of the C-terminal helical bundle domain of PDE5. However, as mentioned above, the orientation of the two compounds within the binding pocket is different (Figures 1B and D) and their interactions are different too. The program LIGPLOT was used to plot the interactions between the compounds and PDE5 (Figures 2A and B).²⁵ Compound **2** only formed the key bidentate H-bonds with residue Q817, while besides these H-bonds compound **5** also interacts with residue Q775 through a water molecule. Compound **5** formed hydrophobic interactions with multiple residues, Y612, L765, V782, A783, F786, M816, and F820 (Figure 2B). The pyrimidinone ring of **5** is located just between the hydrophobic clamp composed of V782 and F820, and has perfect π - π stacking interactions with the phenyl ring of F820 (Figure S2). Two ethyl groups on the pyrimidinone ring simultaneously occupy two sub-pockets SP1 (created primarily by residues L765, I768, and F820) and SP2 (created primarily by residues Y612, H613, V782, and F786) (Figure 2D). However, in the complex of PDE5/**2**, as discussed above, the hydrophobic cyclopentene ring of the compound has to bind to

the sub-pocket SP1 in order to avoid close contact with the crucial water molecule which forms H-bonds with two residues and another water molecule coordinating to Zn^{2+} at the active site of the enzyme (Figures 1B, 1C, 1D, and 2D). The interaction at SP1 results in a shift of the whole compound and thereby breaks the perfect π - π stacking interactions between the pyrimidinone ring and F820 seen in both complexes of PDE5/5 and PDE5/sildenafil. Consequently, hydrophobic interactions were only formed between compound 2 and four residues L725, V782, F786, and F820 (Figure 2A). Compound 2 formed less hydrophobic and H-bond interactions with PDE5, which leads to its much lower potency (only 24% inhibition of PDE5 at 1 μM concentration) than compound 5 (IC_{50} , 1.6 nM). Therefore, the structural analysis of these two compounds together with other inhibitors including sildenafil binding with PDE5 provide new insights into the substrate binding pocket of the catalytic domain. Consideration of the critical water molecule and the two distinct sub-pockets provides a rationale for designing more potent PDE5 inhibitors with new scaffold such as the monocyclic pyrimidinone.

3.2 SAR of substitution at the 6-position of the 4(3H)-pyrimidinone ring.

The initial investigation on the structure-activity relationship (SAR) of the pyrimidin-4(3H)-one derivatives were carried out by substituting the 6-position of the pyrimidinone ring and fixing the

5-[(4-methyl-1-piperazinyl)sulfonyl]-2-propoxyphenyl ring. The inhibition activities of these substituted compounds to PDE5 were presented in Table 1. Compounds **9** and **10** with an amino and a hydroxyl group, respectively, at the 6-position of the 4(3H)-pyrimidinone ring showed little inhibition of PDE5, while compound **11** bearing an acetamido group had a great increase in potency, with an IC_{50} of 450 nM, suggesting that a hydrophilic substitution at this position is unfavorable to the interaction of inhibitors with the residues in the substrate binding pocket. After the hydrophilic group was replaced by other hydrophobic groups, the resulted compounds **12-16** displayed more potent inhibition activity to PDE5 than those of **2**, **9**, and **10**, which is consistent with our structural understanding mentioned above that the substitute on the 6-position of the pyrimidinone ring tends to form hydrophobic interactions with the enzyme and it indeed binds into the SP2 sub-pocket which has been seen in the PDE5/5 complex structure. Compounds **13** and **15** showed higher PDE5 inhibitory activity than **12**, **14**, and **16**, indicating that the length of alkyl maybe influence the interaction with the sub-pocket and the 2-carbon substituent such as an ethyl group or i-propyl group may be suitable for the pocket. Furthermore, replacing the alkyl group with a phenyl group resulted in a decrease in potency (compound **17**), which also implies that the sub-pocket is more favorable in holding an alkyl substituent than an aromatic ring. In the case of

compound **18**, a significant loss of potency in comparison with that of **12** might be ascribed to the partial loss of the stacking interaction of the phenyl ring of F820 with the pyrimidinone moiety because of the lack of electron in the pyrimidinone ring caused by the substitution of the strongly electron-withdrawing trifluoromethyl group in this compound.

3.3 SAR of substitution at 5-position of the 4(3H)-pyrimidinone ring

On the basis of the above results, we decided to retain the 2-carbon chain, the ethyl or i-propyl group, at the 6-position while surveying various 5-substituted pyrimidin-4(3H)-ones, and the results are summarized in Table 2. The introduction of an acetylamino group at the 5-position of pyrimidin-4(3H)-one drastically decreased the potency in comparison with that of **13**. It was quickly discovered that introducing a halogen atom except for fluorin at the 5-position led to a remarkable increase in potency comparable to or even higher than that of **13**. Among them, the iodo derivative, compound **23**, has the highest IC₅₀ of 7.2 nM. Most significantly, we find that compound **5** with an ethyl group at both the 6- and 5-position of the pyrimidin-4(3H)-one ring exhibited better PDE5 inhibitory activity than sildenafil and showed the highest IC₅₀ (1.6 nM) among all the compounds reported in the present study. Compounds **3** and **27** with a shorter and longer alkyl group than 2-carbon one, respectively, both had less inhibitory activity to PDE5 than that of **5**, indicating that the sub-pocket of the enzyme to accommodate the

substituted group at the 5-position of the pyrimidin-4(3H)-one ring is also favorable in interaction with an 2-carbon alkyl group, which is verified by the crystal structure of PDE5/**5** complex. Although the introduction of an i-propyl group at the 6-position of the pyrimidinone ring in compound **15** resulted in better inhibitor activity than that of **13** with an ethyl group at the same position, compound **29** with an i-propyl group at the 6-position of the pyrimidinone ring showed a potency 2-fold less than **5**. Subsequently, the ethyl group was selected for the 5-position substituent and the methyl and n-propyl groups were individually chosen for the substituent at the 6-position. The compounds **29**, **30**, and **31** had ~2-fold, 8-fold, and 3-fold, respectively, loss in potency in comparison with that of **5**. Therefore, the SAR results presented above indicate that the substituent at both the 5- and the 6-position of the pyrimidin-4(3H)-one moiety are pivotal for determining the inhibition potency of the compounds to PDE5 and consequently, the 5, 6-diethyl-pyrimidin-4(3H)-one showed the strongest inhibition potency among the series of pyrimidin-4(3H)-one analogues.

Using compounds **13** (H), **20** (F), **21**(Cl), **22** (Br), and **23** (I), we have previously reported that the halogen bond formed between the halogen atom of the compound and the hydroxyl oxygen atom of Y612 in the active site of PDE5 plays important role in binding of the inhibitors with PDE5.²³ The order of halogen-binding contribution to IC₅₀ of these

compounds to PDE5 is 23 (I) > 22 (Br) > 21 (Cl) > 20 (F). Here, the chemical structure of compound **5** is similar to those of the four compounds except the substitution at 5-position of the 4(3H)-pyrimidinone ring is an ethyl group, instead of the halogen atoms. The IC₅₀ of compound **5** is even higher than that of compound **23**. It is suggested that the hydrophobic interactions of the ethyl group of **5** with the sub-pocket SP2, mainly composed of the residues F786, V782, Y612, and H613, compensate the missed halogen bonding interactions in PDE5/**5** complex, contributing greatly to the binding affinity of compound **5** with PDE5. It is thereby concluded that the optimization of the substitutions at the 5-position of the 4(3H)-pyrimidinone is important for the potency of the pyrimidin-4(3H)-ones.

3.4 SAR of substitution at the 2'-position of the phenyl ring

In parallel to establishing SAR at the 6- and 5-position substitutions of the pyrimidinone moiety, we devoted a part of effort to evaluating the effect of the o-alkyl side-chain at the 2'-position of the phenyl ring on its hydrophobic interaction with the enzyme. As shown in Table 3, it is clear that a 3-carbon chain in compounds **24** and **25** resulted in high inhibition potency to PDE5. Therefore, the n-propoxyl group is selected for the substitution at the 2'-position of the phenyl ring of the inhibitors, which contributes the proper hydrophobic interaction with PDE5.

3.5 Selectivity and in vivo study of compound **5**

The inhibitions of compound **5** versus 11 PDEs were measured by using sildenafil as a control (Table 4). The inhibition of the compound to PDE2, PDE3, PDE4, PDE7A1, PDE8A1, PDE9A2, PDE10A2 is very weak ($IC_{50} > 10000$ nM). The IC_{50} of **5** to PDE11A4, PDE1, and PDE6C are 2127-, 469-, and 29-fold higher than the IC_{50} of this compound to PDE5A, respectively. The selectivity profile of sildenafil to the 11 PDEs is similar to that of compound **5**.

With excellent enzyme inhibition of PDE5 and also good selectivity over other PDEs in vitro, compound **5** was selected for further testing in vivo. The pharmacokinetic data of compound **5** is summarized in Table 5 and the profile generated based on these data is shown in Figure 3. After oral administration of a 10 mg/kg dose of **5** to male rats, a C_{max} of 468 ng/ml was obtained at 20 min, and the oral bioavailability of the compound was 10.0%, lower than that of sildenafil (23%)²⁶.

In vivo efficacy of compound **5** was evaluated in the rat model of erection (Figure 4). Intracavernous pressure (ICP) and arterial blood pressure (BP) were simultaneously monitored during electric stimulation before and after the oral administration of compound **5**. At a dose of 10 mg/kg, compound **5** significantly increased the ICP/BP value at 30 min, compared to vehicle. It showed a good efficacy as sildenafil did.

3. CONCLUSIONS

The structural analysis based on crystal structures of the PDE5

1
2
3
4 catalytic domain in complex with our compounds as well as other
5
6 well-known PDE5 inhibitors revealed new characteristics of the inhibitor
7
8 binding pocket. This includes the two separated sub-pockets and a crucial
9
10 water molecule, which enable us to design the monocyclic
11
12 pyrimidin-4(3H)-one as a new scaffold to synthesize the novel, potent,
13
14 and selective PDE5 inhibitors. Systematical exploration of SAR of the
15
16 substitutions on the pyrimidine-4(3H)-one moiety resulted in the
17
18 identification of 25 compounds with IC₅₀ ranging from 1 to 100 nM and
19
20 11 compounds with IC₅₀ ranging from 1 to 10 nM. In particular, the
21
22 compound **5** has the best IC₅₀, with a value of 1.6 nM, among all these
23
24 compounds. The crystal structures of PDE5/**5**, PDE5/**2**, and
25
26 PDE5/sildenafil complexes confirmed our rationale to design simpler
27
28 monocyclic pyrimidin-4(3H)-ones working as potent inhibitors of PDE5.
29
30 The structures also revealed that simultaneously occupying two
31
32 sub-pockets by two ethyl groups of monocyclic pyrimidin-4(3H)-ones
33
34 compensated the H-bond formed with the crucial water molecule which
35
36 has been seen in the PDE5/sildenafil complex but missed in
37
38 pyrimidin-4(3H)-ones in complex with PDE5. Moreover, in vivo efficacy
39
40 studies have revealed that compound **5** exhibited a significant effect on
41
42 intracavernosal pressure in rats. Further investigation to improve the
43
44 druggability of this compound through structural modification to seek a
45
46 potential candidate for clinical study is ongoing.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

4. EXPERIMENTAL SECTION

5.1 Chemistry

¹H-NMR spectra was determined using a Mercury 300 MHz, FT NMR spectrometer. HRMS were performed on a Finnigan MAT95 mass spectrometer. Reaction solvents were purchased and used without further purification. HPLC conditions were as follows: column, YMC-Pack CN 5 μ M, 4.6 mm $\times$ 250 mm; solvent system, (A) MeCN; (B) 0.02 M KH₂PO₄ (pH 6.0); step gradient, time 0, 30% A; time 20 min, 70% A; stop time, 25 min; flow rate 1.0 mL/min; UV detection, 220 nm; injection volume, 5 μ L; temperature, 30 °C. The purity of all target compounds was >95% as confirmed by HPLC.

General Procedure for the Synthesis of **2**, **3**, **5**, **9**, **10**, **12-20** and **27-31**

2-[2-n-propoxy-5-(4-methyl-1-piperazinylsulfonyl)phenyl]cyclopentapyrimid-4(3H)-one (2) A mixture of

5-(4-methylpiperazin-1-ylsulfonyl)-2-propoxybenzimidamide (340 mg, 1 mmol), ethyl 2-oxo-cyclopentane-1-carboxylate (312 mg, 2 mmol), and potassium carbonate (276 mg, 2 mmol) in N,N-Dimethylformamide (5 mL) was stirred at 100 °C for 4 h. After cooled to room temperature, the reaction mixture was poured into ice water, and extracted with dichloromethane (3 $\times$ 10 ml). The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated. The residue was purified by flash column chromatography. After crystallization from

ethyl acetate, compound **2** was obtained as a white solid (84 mg, yield: 19%).

$^1\text{H-NMR}$ (CDCl_3) δ : 10.96 (1H, br), 8.84 (1H, d), 7.82 (1H, dd), 7.15 (1H, d), 4.25 (2H, t), 3.09 (4H, br), 2.93 (2H, t), 2.85 (2H, t), 2.51 (4H, br), 2.28 (3H, s), 2.16-1.98 (4H, m), 1.15 (3H, t). HRMS (ESI) calcd $[\text{M} + \text{H}]^+$ for $\text{C}_{21}\text{H}_{29}\text{N}_4\text{O}_4\text{S}$ 433.1910, found 433.1916.

5-methyl-6-ethyl-2-[2-n-propoxy-5-(4-methyl-1-piperazinylsulfonyl)phenyl]pyrimid-4(3H)-one (3)

Compound **3** was prepared in 63% yield from ethyl 2-methylpropionylacetate and

5-(4-methylpiperazin-1-ylsulfonyl)-2-propoxybenzimidamide following a similar procedure to that described for synthesis of **2**. $^1\text{H-NMR}$ (CDCl_3) δ : 11.02 (1H, br), 8.78 (1H, d), 7.80 (1H, dd), 7.14 (1H, d), 4.22 (2H, t), 3.10 (4H, br), 2.65 (2H, q), 2.54 (4H, br), 2.30 (3H, s), 2.09 (3H, s), 1.99 (2H, m), 1.23 (3H, t), 1.12 (3H, t). HRMS (ESI) calcd $[\text{M} + \text{H}]^+$ for $\text{C}_{21}\text{H}_{31}\text{N}_4\text{O}_4\text{S}$ 435.2066, found 435.2066.

5,6-diethyl-2-[2-n-propoxy-5-(4-methyl-1-piperazinylsulfonyl)phenyl]pyrimid-4(3H)-one (5)

Compound **5** was prepared in 65% yield from ethyl 2-ethylpropionylacetate and

5-(4-methylpiperazin-1-ylsulfonyl)-2-propoxybenzimidamide following a similar procedure to that described for synthesis of **2**. $^1\text{H-NMR}$ ($\text{DMSO}-d_6$) δ : 12.06 (1H, br), 7.88 (1H, d), 7.82 (1H, dd), 7.38 (1H, d), 4.12 (2H, t), 2.88 (4H, br), 2.57 (2H, q), 2.46 (2H, q), 2.36 (4H, br), 2.14

(3H, s), 1.75 (2H, m), 1.17 (3H, t), 1.04 (3H, t), 0.96 (3H, t). HRMS (ESI) calcd $[M + H]^+$ for $C_{22}H_{33}N_4O_4S$ 449.2223, found 449.2227.

6-amino-2-[2-n-propoxy-5-(4-methyl-1-piperazinylsulfonyl)phenyl]pyrimid-4(3H)-one (9) Compound **9** was prepared in 38% yield from ethyl cyanoacetate and

5-(4-methylpiperazin-1-ylsulfonyl)-2-propoxybenzimidamide following a similar procedure to that described for synthesis of **2**. 1H -NMR

(DMSO- d_6) δ : 11.25 (1H, br), 7.90 (1H, d), 7.81 (1H, dd), 7.38 (1H, d), 6.56 (2H, br), 5.00 (1H, s), 4.12 (2H, t), 2.87 (4H, br), 2.36 (4H, br), 2.14 (3H, s), 1.75 (2H, m), 0.97 (3H, t). HRMS (ESI) calcd $[M + H]^+$ for $C_{18}H_{26}N_5O_4S$ 408.1706, found 408.1709.

6-hydroxy-2-[2-n-propoxy-5-(4-methyl-1-piperazinylsulfonyl)phenyl]pyrimid-4(3H)-one (10) Compound **10** was prepared in 41% yield from diethyl malonate and

5-(4-methylpiperazin-1-ylsulfonyl)-2-propoxybenzimidamide following a similar procedure to that described for synthesis of **2**. 1H -NMR

(DMSO- d_6) δ : 8.09 (1H, d), 7.76 (1H, dd), 7.36 (1H, d), 4.52 (1H, s), 4.15 (2H, t), 2.87 (4H, br), 2.36 (4H, br), 2.13 (3H, s), 1.79 (2H, m), 1.01 (3H, t). HRMS (ESI) calcd $[M + H]^+$ for $C_{18}H_{25}N_4O_5S$ 409.1546, found 409.1549.

6-methyl-2-[2-n-propoxy-5-(4-methyl-1-piperazinylsulfonyl)phenyl]pyrimid-4(3H)-one (12) Compound **12** was prepared in 62% yield from

ethyl acetoacetate and

5-(4-methylpiperazin-1-ylsulfonyl)-2-propoxybenzimidamide following a similar procedure to that described for synthesis of **2**. $^1\text{H-NMR}$ (CDCl_3) δ : 11.03 (1H, br), 8.83 (1H, d), 7.85 (1H, dd), 7.16 (1H, d), 6.23 (1H, s), 4.25 (2H, t), 3.07 (4H, br), 2.48 (4H, br), 2.35 (3H, s), 2.26 (3H, s), 2.03 (2H, m), 1.14 (3H, t). HRMS (ESI) calcd $[\text{M} + \text{H}]^+$ for $\text{C}_{19}\text{H}_{27}\text{N}_4\text{O}_4\text{S}$ 407.1753, found 407.1744.

6-ethyl-2-[2-n-propoxy-5-(4-methyl-1-piperazinylsulfonyl)phenyl]pyrimid-4(3H)-one (13) Compound **13** was prepared in 60% yield from ethyl propionylacetate and

5-(4-methylpiperazin-1-ylsulfonyl)-2-propoxybenzimidamide following a similar procedure to that described for synthesis of **2**. $^1\text{H-NMR}$ ($\text{DMSO}-d_6$) δ : 7.89 (1H, d), 7.84 (1H, dd), 7.39 (1H, d), 4.15 (2H, t), 2.89 (4H, br), 2.45 (2H, q), 2.36 (4H, br), 2.16 (3H, s), 1.75 (2H, m), 1.13 (3H, t), 0.96 (3H, t). HRMS (ESI) calcd $[\text{M} + \text{Na}]^+$ for $\text{C}_{20}\text{H}_{29}\text{N}_4\text{O}_4\text{NaS}$ 443.1729, found 443.1736.

6-n-propyl-2-[2-n-propoxy-5-(4-methyl-1-piperazinylsulfonyl)phenyl]pyrimid-4(3H)-one (14) Compound **14** was prepared in 58% yield from ethyl butyrylacetate and

5-(4-methylpiperazin-1-ylsulfonyl)-2-propoxybenzimidamide following a similar procedure to that described for synthesis of **2**. $^1\text{H-NMR}$ (CDCl_3) δ : 11.01 (1H, br), 8.85 (1H, d), 7.85 (1H, dd), 7.15 (1H, d), 6.22 (1H, d),

4.25 (2H, t), 3.07 (4H, br), 2.56 (2H, t), 2.48 (4H, br), 2.26 (3H, s), 2.03 (2H, m), 1.74 (2H, m), 1.14 (3H, t), 0.98 (3H, t). HRMS (ESI) calcd $[M + Na]^+$ for $C_{21}H_{30}N_4O_4SNa$ 457.1885, found 457.1898.

6-isopropyl-2-[2-n-propoxy-5-(4-methyl-1-piperazinylsulfonyl)phenyl]pyrimid-4(3H)-one (15) Compound **15** was prepared in 55% yield from

ethyl isobutyrylacetate and

5-(4-methylpiperazin-1-ylsulfonyl)-2-propoxybenzimidamide following a similar procedure to that described for synthesis of **2**. 1H -NMR ($CDCl_3$) δ : 10.99 (1H, br), 8.87 (1H, d), 7.86 (1H, dd), 7.15 (1H, d), 6.24 (1H, s), 4.25 (2H, t), 3.08 (4H, br), 2.83 (1H, m), 2.49 (4H, br), 2.26 (3H, s), 2.03 (2H, m), 1.26 (6H, d), 1.15 (3H, t). HRMS (ESI) calcd $[M + H]^+$ for $C_{21}H_{31}N_4O_4S$ 435.2066, found 435.2069.

6-isobutyl-2-[2-n-propoxy-5-(4-methyl-1-piperazinylsulfonyl)phenyl]pyrimid-4(3H)-one (16) Compound **16** was prepared in 65% yield from

ethyl isovalerylacetate and

5-(4-methylpiperazin-1-ylsulfonyl)-2-propoxybenzimidamide following a similar procedure to that described for synthesis of **2**. 1H -NMR ($CDCl_3$) δ : 11.02 (1H, br), 8.86 (1H, d), 7.86 (1H, dd), 7.15 (1H, d), 6.19 (1H, s), 4.25 (2H, t), 3.07 (4H, br), 2.48 (4H, br), 2.44 (2H, d), 2.26 (3H, s), 2.13 (1H, m), 2.01 (2H, m), 1.15 (3H, t), 0.96 (6H, d). HRMS (ESI) calcd $[M + H]^+$ for $C_{22}H_{33}N_4O_4S$ 449.2223, found 449.2210.

6-phenyl-2-[2-n-propoxy-5-(4-methyl-1-piperazinylsulfonyl)phenyl]p

pyrimid-4(3H)-one (17) Compound **17** was prepared in 67% yield from ethyl benzoylacetate and 5-(4-methylpiperazin-1-ylsulfonyl)-2-propoxybenzimidamide following a similar procedure to that described for synthesis of **2**. $^1\text{H-NMR}$ ($\text{DMSO-}d_6$) δ : 12.44 (1H, br), 8.10-8.05 (2H, m), 8.01 (1H, d), 7.87 (1H, dd), 7.53-7.47 (3H, m), 7.43 (1H, d), 6.91 (1H, s), 4.15 (2H, t), 2.92 (4H, br), 2.37 (4H, br), 2.14 (3H, s), 1.76 (2H, m), 0.95 (3H, t). HRMS (ESI) calcd $[\text{M} + \text{H}]^+$ for $\text{C}_{24}\text{H}_{28}\text{N}_4\text{O}_4\text{S}$ 469.1910, found 469.1916.

6-trifluoromethyl-2-[2-n-propoxy-5-(4-methyl-1-piperazinylsulfonyl)phenyl]pyrimid-4(3H)-one (18) Compound **18** was prepared in 37% yield from ethyl 4,4,4-trifluoroacetoacetate and 5-(4-methylpiperazin-1-ylsulfonyl)-2-propoxybenzimidamide following a similar procedure to that described for synthesis of **2**. $^1\text{H-NMR}$ (CDCl_3) δ : 8.84 (1H, d), 7.92 (1H, dd), 7.19 (1H, d), 6.75 (1H, s), 4.29 (2H, t), 3.08 (4H, br), 2.49 (4H, br), 2.27 (3H, s), 2.04 (2H, m), 1.17 (3H, t). HRMS (ESI) calcd $[\text{M} + \text{H}]^+$ for $\text{C}_{19}\text{H}_{24}\text{F}_3\text{N}_4\text{O}_4\text{S}$ 461.1470, found 461.1470.

5-acetamido-6-ethyl-2-[2-n-propoxy-5-(4-methyl-1-piperazinylsulfonyl)phenyl]pyrimid-4(3H)-one (19) Compound **19** was prepared in 42% yield from ethyl 2-acetamidopropionylacetate and 5-(4-methylpiperazin-1-ylsulfonyl)-2-propoxybenzimidamide following a similar procedure to that described for synthesis of **2**. $^1\text{H-NMR}$ ($\text{DMSO-}d_6$) δ : 12.48 (1H, br), 9.22 (1H, br), 7.88 (1H, d), 7.84 (1H, dd),

7.39 (1H, d), 4.13 (2H, t), 2.91 (4H, br), 2.43 (2H, q), 2.40 (4H, br), 2.16 (3H, s), 2.02 (3H, s), 1.76 (2H, m), 1.13 (3H, t), 0.96 (3H, t). HRMS (ESI) calcd $[M + H]^+$ for $C_{22}H_{32}N_5O_5S$ 478.2124, found 478.2126.

5-fluoro-6-ethyl-2-[2-propoxy-5-(4-methyl-1-piperazinylsulfonyl)phenyl]pyrimidin-4(3H)-one (20) Compound **20** was prepared in 72% yield from methyl 2-fluoro-3-oxopentanoate and 5-(4-methylpiperazin-1-ylsulfonyl)-2-propoxybenzimidamide following following a similar procedure to that described for synthesis of **2**.

1H -NMR ($CDCl_3$) δ : 8.80 (1H, d), 7.86 (1H, dd), 7.16 (1H, d), 4.26 (2H, t), 3.09 (4H, br), 2.74 (2H, q), 2.51 (4H, br), 2.28 (3H, s), 2.03 (2H, m), 1.28 (3H, t), 1.15 (3H, t). HRMS (ESI) calcd $[M + Na]^+$ for $C_{20}H_{27}N_4O_4NaSF$ 461.1635, found 461.1630.

5-propyl-6-ethyl-2-[2-n-propoxy-5-(4-methyl-1-piperazinylsulfonyl)phenyl]pyrimidin-4(3H)-one (27) Compound **27** was prepared in 39% yield from ethyl 2-propylpropionylacetate and 5-(4-methylpiperazin-1-ylsulfonyl)-2-propoxybenzimidamide following a similar procedure to that described for synthesis of **2**. 1H -NMR ($CDCl_3$) δ : 10.97 (1H, br), 8.84 (1H, d), 7.82 (1H, dd), 7.13 (1H, d), 4.23 (2H, t), 3.07 (4H, br), 2.65 (2H, q), 2.52 (2H, t), 2.49 (4H, br), 2.26 (3H, s), 2.02 (2H, m), 1.55 (2H, m), 1.26 (3H, t), 1.15 (3H, t), 0.99 (3H, t). HRMS (ESI) calcd $[M + H]^+$ for $C_{23}H_{35}N_4O_4S$ 463.2379, found 463.2379.

5-methyl-6-isopropyl-2-[2-n-propoxy-5-(4-methyl-1-piperazinylsulfonyl)phenyl]pyrimidin-4(3H)-one (28)

yl)phenyl]pyrimid-4(3H)-one (28) Compound **28** was prepared in 54% yield from ethyl 2-methylisobutyrylacetate and 5-(4-methylpiperazin-1-ylsulfonyl)-2-propoxybenzimidamide following a similar procedure to that described for synthesis of **2**. $^1\text{H-NMR}$ (CDCl_3) δ : 10.93 (1H, br), 8.86 (1H, d), 7.83 (1H, dd), 7.13 (1H, d), 4.24 (2H, t), 3.16 (1H, m), 3.08 (4H, br), 2.48 (4H, br), 2.26 (3H, s), 2.12 (3H, s), 2.02 (2H, m), 1.22 (6H, d), 1.15 (3H, t). HRMS (ESI) calcd $[\text{M} + \text{H}]^+$ for $\text{C}_{22}\text{H}_{33}\text{N}_4\text{O}_4\text{S}$ 449.2223, found 449.2227.

5-ethyl-6-isopropyl-2-[2-n-propoxy-5-(4-methyl-1-piperazinylsulfonyl)phenyl]pyrimid-4(3H)-one (29) Compound **29** was prepared in 41% yield from ethyl 2-ethylisobutyrylacetate and 5-(4-methylpiperazin-1-ylsulfonyl)-2-propoxybenzimidamide following a similar procedure to that described for synthesis of **2**. $^1\text{H-NMR}$ (CDCl_3) δ : 10.95 (1H, br), 8.85 (1H, d), 7.82 (1H, dd), 7.13 (1H, d), 4.23 (2H, t), 3.15 (1H, m), 3.07 (4H, br), 2.58 (2H, q), 2.47 (4H, br), 2.25 (3H, s), 2.02 (2H, m), 1.23 (6H, d), 1.14 (3H, t), 1.12 (3H, t). HRMS (ESI) calcd $[\text{M} + \text{H}]^+$ for $\text{C}_{23}\text{H}_{35}\text{N}_4\text{O}_4\text{S}$ 463.2379, found 463.2379.

5-ethyl-6-methyl-2-[2-n-propoxy-5-(4-methyl-1-piperazinylsulfonyl)phenyl]pyrimid-4(3H)-one (30) Compound **30** was prepared in 42% yield from ethyl 2-ethylacetoacetate and 5-(4-methylpiperazin-1-ylsulfonyl)-2-propoxybenzimidamide following a similar procedure to that described for synthesis of **2**. $^1\text{H-NMR}$ (CDCl_3) δ :

11.00 (1H, br), 8.77 (1H, d), 7.80 (1H, dd), 7.12 (1H, d), 4.22 (2H, t),
3.05 (4H, br), 2.55 (2H, q), 2.48 (4H, br), 2.37 (3H, s), 2.25 (3H, s), 1.98
(2H, m), 1.13 (3H, t), 1.11 (3H, t). HRMS (ESI) calcd $[M + H]^+$ for
 $C_{21}H_{31}N_4O_4S$ 435.2066, found 435.2068.

5-ethyl-6-propyl-2-[2-n-propoxy-5-(4-methyl-1-piperazinylsulfonyl)phenyl]pyrimid-4(3H)-one (31)

Compound **31** was prepared in 38% yield from ethyl 2-ethylbutyrylacetate and

5-(4-methylpiperazin-1-ylsulfonyl)-2-propoxybenzimidamide following a similar procedure to that described for synthesis of **2**. 1H -NMR ($CDCl_3$) δ : 10.95 (1H, br), 8.82 (1H, d), 7.82 (1H, dd), 7.13 (1H, d), 4.24 (2H, t), 3.07 (4H, br), 2.63-2.55 (4H, m), 2.49 (4H, br), 2.27 (3H, s), 2.03 (2H, m), 1.74 (2H, m), 1.15 (3H, t), 1.14 (3H, t), 1.00 (3H, t). HRMS (ESI) calcd $[M + H]^+$ for $C_{23}H_{35}N_4O_4S$ 463.2379, found 463.2379.

6-Acetamido-2-[2-n-propoxy-5-(4-methyl-1-piperazinylsulfonyl)phenyl]pyrimid-4(3H)-one (11)

The compound **9** (0.20 g, 0.5 mmol) was suspended in acetic anhydride (5 ml), and the mixture was stirred at 100 °C for 1 h. The cooled reaction mixture was poured into ice water to generate a white solid. The solid was collected by filtration, washed with clear water (3×10 ml), and dried at 60 °C to give compound **11** (0.12 g, yield: 54%). 1H -NMR ($DMSO-d_6$) δ : 12.16 (1H, br), 10.54 (1H, br), 7.92 (1H, d), 7.84 (1H, dd), 7.40 (1H, d), 6.89 (1H, s), 4.12 (2H, t), 2.88 (4H, br), 2.36 (4H, br), 2.14 (3H, s), 2.08 (3H, s), 1.74 (2H, m), 0.95 (3H, t).

HRMS (ESI) calcd $[M + H]^+$ for $C_{20}H_{28}N_5O_5S$ 450.1811, found 450.1811.

General Procedure for the Synthesis of **21-26**

5-Chloro-6-ethyl-2-[2-propoxy-5-(4-methyl-1-piperazinylsulfonyl)phenyl]pyrimidin-4(3H)-one (21)

Chlorine gas was bubbled into an ice-cold solution of **13** (100 mg, 0.24 mmol) and pyridine (40 μ L, 0.5 mmol) in dichloromethane (10 mL) for 1 min. The resulting mixture was washed with 1N $Na_2S_2O_3$ (aq, 5 mL) and water (5 mL). The organic layer was dried over anhydrous sodium sulfate and concentrated in vacuo. After crystallization from ethyl acetate, compound **21** was obtained as white crystals (93 mg, yield 85%). 1H -NMR ($CDCl_3$) δ : 11.25 (1H, br), 8.85 (1H, d), 7.87 (1H, dd), 7.16 (1H, d), 4.27 (2H, t), 3.08 (4H, br), 2.85 (2H, q), 2.49 (4H, br), 2.27 (3H, s), 2.03 (2H, m), 1.29 (3H, t), 1.15 (3H, t). HRMS (ESI) calcd $[M + Na]^+$ for $C_{20}H_{27}N_4O_4NaSCl$ 477.1339, found 477.1339.

5-Bromo-6-ethyl-2-[2-propoxy-5-(4-methyl-1-piperazinylsulfonyl)phenyl]pyrimidin-4(3H)-one (22)

Bromine (40 mg, 0.27 mmol) was added to an ice-cold solution of **13** (100 mg, 0.24 mmol) and pyridine (22 μ L, 0.27 mmol) in dichloromethane (10 mL). The mixture was stirred for 15 min at 0°C and washed with 1 N $Na_2S_2O_3$ (aq, 5 mL) and water (5 mL). The organic layer was dried over anhydrous sodium sulfate and concentrated. After crystallization from ethyl acetate, compound **22** was obtained as a white solid (107 mg, yield 90%). 1H -NMR ($CDCl_3$) δ : 11.12

(1H, br), 8.86 (1H, d), 7.88 (1H, dd), 7.16 (1H, d), 4.27 (2H, t), 3.09 (4H, br), 2.88 (2H, q), 2.50 (4H, br), 2.28 (3H, s), 2.03 (2H, m), 1.29 (3H, t), 1.15 (3H, t). HRMS (ESI) calcd $[M + Na]^+$ for $C_{20}H_{27}N_4O_4NaSBr$ 521.0834, found 521.0834.

5-Iodo-6-ethyl-2-[2-propoxy-5-(4-methyl-1-piperazinylsulfonyl)phenyl]

l]pyrimidin-4(3H)-one (23) Iodine (254 mg, 1 mmol) was added to a solution of **13** (420 mg, 1 mmol) and silver nitrate (170 mg, 1 mmol) in methanol (10 mL) at 0°C. The mixture was stirred at room temperature for 30 min. After filtration, the filtrate was poured into water (25 mL) and extracted with dichloromethane (20 mL). The organic layer was washed with 1N $Na_2S_2O_3$ (aq, 5 mL) and water (5 mL), dried, and concentrated. After crystallization from ethyl acetate, **23** was obtained as a white solid (410 mg, 75%). 1H -NMR ($CDCl_3$) δ : 11.12 (1H, br), 8.88 (1H, d), 7.88 (1H, dd), 7.16 (1H, d), 4.27 (2H, t), 3.10 (4H, br), 2.92 (2H, q), 2.52 (4H, br), 2.30 (3H, s), 2.03 (2H, m), 1.28 (3H, t), 1.16 (3H, t). HRMS (ESI) calcd $[M + Na]^+$ for $C_{20}H_{27}N_4O_4NaSI$ 569.0695, found 569.0704.

5-Chloro-6-isopropyl-2-[2-propoxy-5-(4-methyl-1-piperazinylsulfonyl)

]phenyl]pyrimidin-4(3H)-one (24) Compound **24** was prepared in 72% yield from **15** following a similar procedure to that described for synthesis of **21**. 1H -NMR ($CDCl_3$) δ : 11.20 (1H, br), 8.87 (1H, d), 7.89 (1H, dd), 7.17 (1H, d), 4.28 (2H, t), 3.50 (1H, m), 3.10 (4H, br), 2.51 (4H, br), 2.28 (3H, s), 2.05 (2H, m), 1.27 (6H, d), 1.16 (3H, t). HRMS (ESI)

calcd $[M + H]^+$ for $C_{21}H_{30}N_4O_4SCl$ 469.1676, found 469.1676.

5-Bromo-6-isopropyl-2-[2-propoxy-5-(4-methyl-1-piperazinylsulfonyl)

phenyl]pyrimidin-4(3H)-one (25) Compound **25** was prepared in 68%

yield from **15** following a similar procedure to that described for

synthesis of **22**. 1H -NMR ($CDCl_3$) δ : 11.16 (1H, br), 8.86 (1H, d), 7.89

(1H, dd), 7.16 (1H, d), 4.28 (2H, t), 3.50 (1H, m), 3.09 (4H, br), 2.49 (4H,

br), 2.27 (3H, s), 2.03 (2H, m), 1.26 (6H, d), 1.15 (3H, t). HRMS (ESI)

calcd $[M+H]^+$ for $C_{21}H_{30}N_4O_4SBr$ 513.1711, found 513.1715.

5-Iodo-6-isopropyl-2-[2-propoxy-5-(4-methyl-1-piperazinylsulfonyl)p

henyl]pyrimidin-4(3H)-one (26) Compound **26** was prepared in 62%

yield from **15** following a similar procedure to that described for synthesis

of **23**. 1H -NMR ($CDCl_3$) δ : 8.90 (1H, d), 7.89 (1H, dd), 7.16 (1H, d), 4.27

(2H, t), 3.46 (1H, m), 3.09 (4H, br), 2.49 (4H, br), 2.27 (3H, s), 2.04 (2H,

m), 1.25 (6H, d), 1.16 (3H, t).. HRMS (ESI) calcd $[M + H]^+$ for

$C_{21}H_{30}N_4O_4SI$ 561.1032, found 561.1035.

5-Bromo-6-isopropyl-2-[2-ethoxy-5-(4-methyl-1-piperazinylsulfonyl)p

henyl]pyrimidin-4(3H)-one (36) A mixture of 2-ethoxybenzonitrile

(20.5 g, 0.14 mol), potassium carbonate (38.5 g, 0.28 mol), and

hydroxylamine hydrochloride (19.2 g, 0.28 mol) in a mixed solution of

ethanol (100 mL) and water (100 mL) was refluxed for 10 h and the

ethanol was removed by vacuum distillation. After the residue was cooled,

white solid **32a** (18.1 g, 72%) was separated out and collected by

1
2
3
4 filtration.

5
6 The solid **32a** (18 g, 0.5 mol) was solved in acetic acid (200 mL) and
7
8 degassed. A catalytic amount of 10% Pd/C was added, and the solution
9
10 was placed on the shaker under 3 MPa hydrogen at 65°C for 8h. After the
11
12 solvent was removed by vacuum distillation, the residue was **33a** acetate
13
14 (13.2 g, 80%) which was not purified.
15
16

17
18 A mixture of **33a** acetate (9.4g, 42mmol), ethyl isobutyrylacetate (7.3 g,
19
20 46 mmol), and potassium carbonate (11.6 g, 84 mmol) in
21
22 N,N-Dimethylformamide (80 mL) was stirred at 100°C for 4 h. The
23
24 mixture was then cooled to room temperature and taken up in water (400
25
26 mL), and the solid was collected by filtration and purified by
27
28 recrystallization from ethyl acetic to yield **34a** (7.7 g, 71%) as white solid.
29
30
31 ¹H-NMR (CDCl₃) δ: 11.22 (1H, br), 8.52 (1H, dd), 7.48 (1H, t), 7.12 (1H,
32
33 t), 7.03 (1H, d), 6.20 (1H, s), 4.29 (2H, q), 2.82 (1H, m), 1.59 (3H, t),
34
35 1.27 (6H, d).
36
37
38
39

40
41 Bromine (1.9g, 12mmol) was added to an ice-cold solution of **34a** (3.2 g,
42
43 12 mmol) and pyridine (1 mL) in dichloromethane (150 mL). The
44
45 mixture was stirred for 10min at 0°C and washed with 1 N Na₂S₂O₃ (aq,
46
47 45 mL) and water (50 mL). The organic layer was dried over anhydrous
48
49 sodium sulfate and concentrated. After crystallization from
50
51 ether-acetonitrile, **35a₁** (3.3 g, yield 82%) was obtained. ¹H-NMR (CDCl₃)
52
53 δ: 8.53 (1H, d), 7.51 (1H, t), 7.13 (1H, t), 7.04 (1H, d), 4.32 (2H, q), 3.51
54
55
56
57
58
59
60

(1H, m), 1.59 (3H, t), 1.27 (6H, d).

Compound **35a₁** (0.34 g, 1 mmol) was added portion-wise to an ice-cold chlorosulfonic acid (2 mL). The resulting mixture was stirred for 2 h at 0°C and then was added dropwise to crushed ice. The mixture was extracted by dichloromethane and the organic layer was added dropwise to a solution of 1-methylpiperazine (0.11 g, 1.1 mmol) and triethylamine (1 mL) in dichloromethane (30 mL) at 0°C. After stirred at 0°C for 10 min, the reaction mixture was washed with water, dried over anhydrous sodium sulfate and concentrated to give a crude product. After crystallization from ethyl acetate, **36** was yielded (0.38 g, 76%). ¹H-NMR (DMSO-*d*₆) δ: 7.91 (1H, d), 7.85 (1H, dd), 7.39 (1H, d), 4.21 (2H, q), 3.36 (1H, m), 2.90 (4H, br), 2.36 (4H, br), 2.14 (3H, s), 1.35 (3H, t), 1.17 (6H, d). HRMS (ESI) calcd [M + H]⁺ for C₂₀H₂₈N₄O₄SBr 499.1015, found 499.1017.

5-Bromo-6-isopropyl-2-[2-butoxy-5-(4-methyl-1-piperazinylsulfonyl)phenyl]pyrimidin-4(3H)-one (37) Compound **37** was prepared from 2-butoxybenzonitrile following a similar procedure to that described for **36**. ¹H-NMR (DMSO-*d*₆) δ: 7.89 (1H, d), 7.85 (1H, dd), 7.39 (1H, d), 4.14 (2H, t), 3.37 (1H, m), 2.90 (4H, br), 2.37 (4H, br), 2.14 (3H, s), 1.71 (2H, m), 1.35 (2H, m), 1.23 (3H, m), 1.15 (6H, d), 0.81 (3H, t). HRMS (ESI) calcd [M + H]⁺ for C₂₂H₃₂N₄O₄SBr 527.1328, found 527.1330.

5-Bromo-6-isopropyl-2-[2-hexoxy-5-(4-methyl-1-piperazinylsulfonyl)

phenyl]pyrimidin-4(3H)-one (38) Compound **38** was prepared from 2-hexoxybenzonitrile following a similar procedure to that described for **36**. ¹H-NMR (DMSO- *d*₆) δ : 7.89 (1H, d), 7.85 (1H, dd), 7.39 (1H, d), 4.14 (2H, t), 3.37 (1H, m), 2.90 (4H, br), 2.37 (4H, br), 2.14 (3H, s), 1.70 (2H, m), 1.35 (2H, m), 1.28-1.19 (4H, m), 1.15 (6H, d), 0.81 (3H, t). HRMS calcd [M + H]⁺ for C₂₄H₃₆N₄O₄SBr 555.1641, found 555.1639.

5-Chloro-6-isopropyl-2-[2-ethoxy-5-(4-methyl-1-piperazinylsulfonyl)

phenyl]pyrimidin-4(3H)-one (39) Chlorine gas was bubbled into an ice-cold solution of **34a** (0.52 g, 2 mmol) and pyridine (0.5 mL) in dichloromethane (20 mL) for 3 min. The resulting mixture was washed with 1N Na₂S₂O₃ (aq, 5 mL) and 1M hydrochloro acid (5 mL). The organic layer was dried over anhydrous sodium sulfate and concentrated in vacuo. After crystallization from ether-acetonitrile, **35a₂** was obtained (0.57 g, 98%). ¹H-NMR (CDCl₃) δ : 8.52 (1H, d), 7.50 (1H, t), 7.13 (1H, t), 7.04 (1H, d), 4.31 (2H, q), 3.49 (1H, m), 1.59 (3H, t), 1.27 (6H, d).

Compound **39** was prepared in 70% from **35a₂** following a similar procedure to that described for **36**. ¹H-NMR (DMSO- *d*₆) δ : 7.91 (1H, d), 7.84 (1H, dd), 7.39 (1H, d), 4.21 (2H, q), 3.36 (1H, m), 2.90 (4H, br), 2.37 (4H, br), 2.14 (3H, s), 1.34 (3H, t), 1.17 (6H, d). HRMS (ESI) calcd [M + H]⁺ for C₂₀H₂₈N₄O₄SCl 455.1520, found 455.1523.

5.2 Protein purification and crystallization

Production of the catalytic domain of recombinant human PDE5A1

1
2
3 followed the protocols of Wang *et. al.*⁹ with certain modifications. Briefly,
4
5 a cDNA fragment encoding PDE5A1 residues 535-860 was cloned into
6
7 the vector pET15b and the protein was expressed in *E.coli*. The expressed
8
9 PDE5A1 was passed through a Ni-NTA column (Qiagen), subjected to
10
11 thrombin cleavage, and further purified by Q-Sepharose and Superdex75
12
13 (GE). The recombinant PDE5A1 with a purity of > 95% was concentrated
14
15 to ~10 mg/ml for further crystallization. Crystallization of apo PDE5A1
16
17 was performed at room temperature using the hanging drop
18
19 vapor-diffusion method, by mixing equal volumes of the protein and of
20
21 the precipitant (19-20% (w/v) PEG 3350/200 mM MgSO₄/100 mM
22
23 Tris-HCl at pH 7.5. To obtain a crystalline complex with **2** and **5**, a 5 mM
24
25 solution of the inhibitor in DMSO was diluted 10-fold, to 0.5 mM, in the
26
27 precipitant solution so as to generate a soaking drop. The crystal was
28
29 transferred into the soaking drop and left for 24 h prior to data collection.
30
31
32
33
34
35
36
37
38

39 **5.3 Structure determination and refinement**

40
41 Data were collected at 100 K on beamline BL17U at the Shanghai
42
43 Synchrotron Radiation Facility (SSRF) and were processed with the
44
45 XDS²⁷ software package. The structures were solved by molecular
46
47 replacement, using the program PHASER²⁸ with the search model of pdb
48
49 code 1T9R²⁹. The structure was refined with the simulated-annealing
50
51 protocol implemented in the program PHENIX³⁰. With the aid of the
52
53 program Coot³¹, inhibitors, water molecules, and others were fitted into to
54
55
56
57
58
59
60

the initial F_o - F_c map. The complete statistics, as well as the quality of the two solved structures, are shown in Table S1.

5.4 Bioassay

The synthesized compounds were evaluated for their inhibitory activities against PDE5 isolated from rabbit platelet using [3 H]cGMP SPA kit. The experiments were detailed in the Supporting Information.

ASSOCIATED CONTENT

Supporting Information. Table S1, Figures S1, Figure S2, PDE Assays, in vivo efficacy in the rat model, pharmacokinetics and HPLC of novel compounds. This material is available free of charge via the Internet at <http://pubs.acs.org>.

AUTHOR INFORMATION

Corresponding Author

*For H.J.: phone, +86 21 50805873; e-mail, hljiang@mail.shcnc.ac.cn.

For Y.X.: phone, +86 21 50801267; e-mail, ycxu@mail.shcnc.ac.cn. For

J.S.: phone, +86 21 20231962; e-mail, jsshcn@mail.shcnc.ac.cn.

Author Contributions

#These authors contributed equally to this study.

ACKNOWLEDGMENTS

This study was supported by the “100 Talents Project” of CAS (to Y.X.), the National Science and Technology Major Project (No.2009ZX09102-056 and 2012ZX09301001-001), the National

High-tech R&D Program (863 Program) (No.2007AA02Z145), the National Natural Science Foundation of China (No. 91013010 and 21172233), the Key Project of Shanghai Science and Technology Commission for Fundamental Research and Development (No. 08JC1422400), Innovation Fund for Technology Based Firms of Shanghai City (No. 1002H117400).

ABBREVIATIONS USED

PDE5, phosphodiesterase type 5; cGMP, cyclic guanosine monophosphate; ED, erectile dysfunction; PAH, pulmonary arterial hypertension; LUTS, lower urinary tract symptoms; BPH, benign prostatic hyperplasia; ICP, Intracavernous pressure; BP, blood pressure.

REFERENCES

- (1). Lin, C. S., Tissue expression, distribution, and regulation of PDE5. *Int J Impot Res* **2004**, *16 Suppl 1*, S8-S10.
- (2). Kouvelas, D.; Goulas, A.; Papazisis, G.; Sardeli, C.; Pourzitaki, C., PDE5 inhibitors: in vitro and in vivo pharmacological profile. *Curr Pharm Des* **2009**, *15*, 3464-3475.
- (3). Wallis, R. M.; Corbin, J. D.; Francis, S. H.; Ellis, P., Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. *Am J Cardiol* **1999**, *83*, 3C-12C.

- (4).Mohamed, H. A.; Girgis, N. M.; Wilcken, R.; Bauer, M. R.; Tinsley, H. N.; Gary, B. D.; Piazza, G. A.; Boeckler, F. M.; Abadi, A. H., Synthesis and molecular modeling of novel tetrahydro-beta-carboline derivatives with phosphodiesterase 5 inhibitory and anticancer properties. *J Med Chem* **2011**, *54*, 495-509.
- (5).Giordano, D.; De Stefano, M. E.; Citro, G.; Modica, A.; Giorgi, M., Expression of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in mouse tissues and cell lines using an antibody against the enzyme amino-terminal domain. *Biochim Biophys Acta* **2001**, *1539*, 16-27.
- (6).Rawson, D. J.; Ballard, S.; Barber, C.; Barker, L.; Beaumont, K.; Bunnage, M.; Cole, S.; Corless, M.; Denton, S.; Ellis, D.; Floc'h, M.; Foster, L.; Gosset, J.; Holmwood, F.; Lane, C.; Leahy, D.; Mathias, J.; Maw, G.; Million, W.; Poinard, C.; Price, J.; Russel, R.; Street, S.; Watson, L., The discovery of UK-369003, a novel PDE5 inhibitor with the potential for oral bioavailability and dose-proportional pharmacokinetics. *Bioorg Med Chem* **2012**, *20*, 498-509.
- (7).Rotella, D. P.; Sun, Z.; Zhu, Y.; Krupinski, J.; Pongrac, R.; Seliger, L.; Normandin, D.; Macor, J. E., Optimization of substituted N-3-benzylimidazoquinazolinone sulfonamides as potent and selective PDE5 inhibitors. *J Med Chem* **2000**, *43*, 5037-5043.
- (8).Tollefson, M. B.; Acker, B. A.; Jacobsen, E. J.; Hughes, R. O.; Walker, J. K.; Fox, D. N.; Palmer, M. J.; Freeman, S. K.; Yu, Y.; Bond, B. R.,

- 1-((2,2,2-trifluoroethoxy)ethyl)-1H-pyrazolo[4,3-d]pyrimidines as potent phosphodiesterase 5 (PDE5) inhibitors. *Bioorg Med Chem Lett* **2010**, *20*, 3125-3128.
- (9). Wang, H.; Liu, Y.; Huai, Q.; Cai, J.; Zoraghi, R.; Francis, S. H.; Corbin, J. D.; Robinson, H.; Xin, Z.; Lin, G.; Ke, H., Multiple conformations of phosphodiesterase-5: implications for enzyme function and drug development. *J Biol Chem* **2006**, *281*, 21469-21479.
- (10). Palmer, M. J.; Bell, A. S.; Fox, D. N.; Brown, D. G., Design of second generation phosphodiesterase 5 inhibitors. *Curr Top Med Chem* **2007**, *7*, 405-419.
- (11). Schwartz, B. G.; Kloner, R. A., Drug interactions with phosphodiesterase-5 inhibitors used for the treatment of erectile dysfunction or pulmonary hypertension. *Circulation* **2010**, *122*, 88-95.
- (12). Doggrell, S. A., Comparison of clinical trials with sildenafil, vardenafil and tadalafil in erectile dysfunction. *Expert Opin Pharmacother* **2005**, *6*, 75-84.
- (13). Eardley, I.; Cartledge, J., Tadalafil (Cialis) for men with erectile dysfunction. *Int J Clin Pract* **2002**, *56*, 300-304.
- (14). Gresser, U.; Gleiter, C. H., Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil--review of the literature. *Eur J Med Res* **2002**, *7*, 435-446.
- (15). Giovannoni, M. P.; Vergelli, C.; Biancalani, C.; Cesari, N.;

- Graziano, A.; Biagini, P.; Gracia, J.; Gavalda, A.; Dal Piaz, V., Novel pyrazolopyrimidopyridazinones with potent and selective phosphodiesterase 5 (PDE5) inhibitory activity as potential agents for treatment of erectile dysfunction. *J Med Chem* **2006**, *49*, 5363-5371.
- (16). Pissarnitski, D., Phosphodiesterase 5 (PDE 5) inhibitors for the treatment of male erectile disorder: attaining selectivity versus PDE6. *Med Res Rev* **2006**, *26*, 369-395.
- (17). Sandner, P.; Hutter, J.; Tinel, H.; Ziegelbauer, K.; Bischoff, E., PDE5 inhibitors beyond erectile dysfunction. *Int J Impot Res* **2007**, *19*, 533-543.
- (18). Card, G. L.; England, B. P.; Suzuki, Y.; Fong, D.; Powell, B.; Lee, B.; Luu, C.; Tabrizizad, M.; Gillette, S.; Ibrahim, P. N.; Artis, D. R.; Bollag, G.; Milburn, M. V.; Kim, S. H.; Schlessinger, J.; Zhang, K. Y., Structural basis for the activity of drugs that inhibit phosphodiesterases. *Structure* **2004**, *12*, 2233-2247.
- (19). Sung, B. J.; Hwang, K. Y.; Jeon, Y. H.; Lee, J. I.; Heo, Y. S.; Kim, J. H.; Moon, J.; Yoon, J. M.; Hyun, Y. L.; Kim, E.; Eum, S. J.; Park, S. Y.; Lee, J. O.; Lee, T. G.; Ro, S.; Cho, J. M., Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules. *Nature* **2003**, *425*, 98-102.
- (20). Chen, G.; Wang, H.; Robinson, H.; Cai, J.; Wan, Y.; Ke, H., An insight into the pharmacophores of phosphodiesterase-5 inhibitors from

synthetic and crystal structural studies. *Biochem Pharmacol* **2008**, *75*, 1717-1728.

(21). Wang, H.; Ye, M.; Robinson, H.; Francis, S. H.; Ke, H., Conformational variations of both phosphodiesterase-5 and inhibitors provide the structural basis for the physiological effects of vardenafil and sildenafil. *Mol Pharmacol* **2008**, *73*, 104-110.

(22). Duan, H.; Zheng, J.; Lai, Q.; Liu, Z.; Tian, G.; Wang, Z.; Li, J.; Shen, J., 2-Phenylquinazolin-4(3H)-one, a class of potent PDE5 inhibitors with high selectivity versus PDE6. *Bioorg Med Chem Lett* **2009**, *19*, 2777-2779.

(23). Xu, Z.; Liu, Z.; Chen, T.; Wang, Z.; Tian, G.; Shi, J.; Wang, X.; Lu, Y.; Yan, X.; Wang, G.; Jiang, H.; Chen, K.; Wang, S.; Xu, Y.; Shen, J.; Zhu, W., Utilization of halogen bond in lead optimization: a case study of rational design of potent phosphodiesterase type 5 (PDE5) inhibitors. *J Med Chem* **2011**, *54*, 5607-5611.

(24). Jones, S. M.; Urch, J. E.; Kaiser, M.; Brun, R.; Harwood, J. L.; Berry, C.; Gilbert, I. H., Analogues of thiolactomycin as potential antimalarial agents. *J Med Chem* **2005**, *48*, 5932-5941.

(25). Wallace, A. C.; Laskowski, R. A.; Thornton, J. M., LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. *Protein Eng.* **1995**, *8*, 127-134.

(26). Walker, D. K.; Ackland, M. J.; James, G. C.; Muirhead, G. J.;

Rance, D. J.; Wastall, P.; Wright, P. A., Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man. *Xenobiotica* **1999**, *29*, 297-310.

(27). Kabsch, W., Xds. *Acta Crystallogr. D Biol. Crystallogr.* **2010**, *66*, 125-132.


(28). McCoy, A. J., Solving structures of protein complexes by molecular replacement with Phaser. *Acta Crystallogr D Biol Crystallogr* **2007**, *63*, 32-41.

(29). Zhang, K. Y.; Card, G. L.; Suzuki, Y.; Artis, D. R.; Fong, D.; Gillette, S.; Hsieh, D.; Neiman, J.; West, B. L.; Zhang, C.; Milburn, M. V.; Kim, S. H.; Schlessinger, J.; Bollag, G., A glutamine switch mechanism for nucleotide selectivity by phosphodiesterases. *Mol Cell* **2004**, *15*, 279-286.


(30). Adams, P. D.; Grosse-Kunstleve, R. W.; Hung, L. W.; Ioerger, T. R.; McCoy, A. J.; Moriarty, N. W.; Read, R. J.; Sacchettini, J. C.; Sauter, N. K.; Terwilliger, T. C., PHENIX: building new software for automated crystallographic structure determination. *Acta Crystallogr. D Biol. Crystallogr.* **2002**, *58*, 1948-1954.

(31). Emsley, P.; Cowtan, K., Coot: model-building tools for molecular graphics. *Acta Crystallogr. D Biol. Crystallogr.* **2004**, *60*, 2126-2132.


Schemes

Scheme 1. Discovery of monocyclic pyrimidinones as novel inhibitors of PDE5

Scheme 2. The synthesis of compounds with monocyclic pyrimidinone core




Reagents and conditions: (a) (i) HSO₃Cl, 0 °C; (ii) N-methyl piperazine, Et₃N, DCM, 0 °C; (b) LiHMDS, THF, room temp; (c) K₂CO₃, DMF, 100 °C; (d) Ethyl cyanoacetate, K₂CO₃, DMF, 100 °C; (e) Diethyl malonate, K₂CO₃, DMF, 100 °C; (f) Ac₂O, 80 °C; (g) Cl₂, Et₃N, DCM, 0 °C; or Br₂, Et₃N, DCM, 0 °C; or I₂, AgNO₃, MeOH, room temperature.

Scheme 3. The synthesis of compounds 36-39

Reagents and conditions: (a) Hydroxylamine hydrochloride, K₂CO₃, Methanol, and water; (b) H₂ (3MPa) / Pd-C; (c) Ethyl isobutyrylacetate, K₂CO₃, DMF, 100°C; (d) Cl₂ (g), Et₃N, DCM, 0°C; or Br₂, Et₃N, DCM, 0 °C; (e) (i) HSO₃Cl, 0°C; (ii) N-methyl piperazine, Et₃N, DCM, 0°C.

Tables


Table 1. SAR of substitution at the 6-position of the 4(3H)-pyrimidinone ring



Compound	R ¹	R ²	IC ₅₀ (nM)
Sildenafil	-	-	3.9
2			>1000
9	H	NH ₂	>2000
10	H	OH	>2000
11	H	AcNH	450
12	H	Me	71
13^a	H	Et	52
14	H	n-Pr	65
15	H	i-Pr	31.5
16	H	i-Bu	88
17	H	Ph	104
18	H	CF ₃	312

^aCompound has been reported in our previous study (reference 23).


Table 2. SAR of substitution at the 5-position of the 4(3H)-pyrimidinone ring



Compound	R ¹	R ²	IC ₅₀ (nM)
Sildenafil	-	-	3.9
19	AcNH	Et	>2000
20^a	F	Et	91
21^a	Cl	Et	36
22^a	Br	Et	13
23^a	I	Et	7.2
24	Cl	i-Pr	6.6
25	Br	i-Pr	7.2
26	I	i-Pr	5.8
3	Me	Et	12.5
5	Et	Et	1.6
27	n-Pr	Et	34.3
28	Me	i-Pr	4.8
29	Et	i-Pr	3.0
30	Et	Me	13.7
31	Et	n-Pr	4.8

^aCompounds have been reported in our previous study (reference 23).

Table 3. SAR of substitution at the 2'-position of the phenyl ring



Compound	X	R	IC ₅₀ (nM)
Sildenafil	-	-	3.9
25	Br	n-Pr	7.2
36	Br	Et	8.5
37	Br	n-Bu	41
38	Br	n-Hex	58
24	Cl	n-Pr	6.6
39	Cl	Et	12.6

Table 4. Inhibition selectivity of compound **5** and sildenafil over 11 PDEs

PDEs	IC ₅₀ (nM)	
	5	Sildenafil
PDE5A	1.6	3.9
PDE1	741	230
PDE2	>10000	>10000
PDE3	>10000	7310
PDE4	>10000	5830
PDE6C	45.6	39.2
PDE7A1	>10000	4690
PDE8A1	>10000	>10000
PDE9A2	>10000	>10000
PDE10A2	>10000	>10000
PDE11A4	3360	4210

Table 5. Pharmacokinetic data of compound **5** in Rats

Dose	route	CL	V	MRT _{0-10h}	AUC _{0-10h}	C _{max}	t _{1/2}	T _{max}	F
(mg/kg)		(L/h/kg)	(L/kg)	(h)	(ug/L*h)	(ug/L)	(h)	(h)	(%)
5	iv	1.17±0.35	2.07±0.13	0.81±0.44	4474±1147	-	1.29±0.35	-	-
10	oral	-	-	3.09±0.48	895±376	468±300	3.94±0.65	0.25 (0.25-0.5)	10.0

Data are expressed as mean ± SD (n=3), or median (range).

Figures




Figure 1. A crucial water molecule in the crystal structures of PDE5 in complex with different inhibitors. The complex structures were superimposed by fitting all the C α atoms of the enzyme. (A) The H-bond interactions of the water molecule with sildenafil, side-chain residues, and the other water molecule in the complex structure of PDE5/sildenafil (pdb code 2H42). (B) Superimposition of compound **2** and sildenafil as well as the crucial water molecule. (C) Superimposition of inhibitors in five complex structures with pdb codes 1UDT (cyan), 2H42 (green), 1RKP (magenta), 3BJC (yellow), and 3B2R (wheat). The water molecules at the same location in these five complex structures as well as in the apo structure (pdb code 2H40, red) are shown as colored balls. SP1 and SP2 represent two sub-pockets that interact with substituents of the

pyrazol, pyrrole or other heterocyclic rings of the inhibitors. (D)

Superimposition of compound **5** with sildenafil as well as the key water molecule.




Figure 2. The interactions between two compounds (**2** and **5**) and PDE5 in crystal structures of their complexes. (A, B) LIGPLOT representations of the interactions of compounds **2** (A) and **5** (B) with the enzyme. (C, D) Molecular surface of the binding pockets for compounds **2** (C) and **5** (D) in their complex structures with the PDE5 catalytic domain. The crucial water molecule is shown as a red ball and the H-bonds formed between it and the residues are labeled with black dash lines.




Figure 3. Mean plasma concentrations of compound **5** in male rat, after single p.o. 10 mg/kg (◆) & i.v 5 mg/kg (●). Data used to generate the profile are the Mean±SD from three male rats (individual samples at all time points).







Figure 4. Effect of compound **5** on ICP/BP 30 min after p.o. administration (10 mg/kg) in the rat erection model. Data are expressed as Mean ± SD (n=3). Percentage increase: $\frac{(\text{ICP/BP})_{\text{after}} - (\text{ICP/BP})_{\text{before}}}{(\text{ICP/BP})_{\text{before}}} \times 100\%$, *: compared with vehicle $P < 0.05$, student's t-test.

Table of Contents






Compound	R ¹	R ²	IC ₅₀ (nM)
Sildenafil	-	-	3.9
2			>1000
9	H	NH ₂	>2000
10	H	OH	>2000
11	H	AcNH	450
12	H	Me	71
13^a	H	Et	52
14	H	n-Pr	65
15	H	i-Pr	31.5
16	H	i-Bu	88
17	H	Ph	104
18	H	CF ₃	312




Compound	R ¹	R ²	IC ₅₀ (nM)
Sildenafil	-	-	3.9
19	AcNH	Et	>2000
20^a	F	Et	91
21^a	Cl	Et	36
22^a	Br	Et	13
23^a	I	Et	7.2
24	Cl	i-Pr	6.6
25	Br	i-Pr	7.2
26	I	i-Pr	5.8
3	Me	Et	12.5
5	Et	Et	1.6
27	n-Pr	Et	34.3
28	Me	i-Pr	4.8
29	Et	i-Pr	3.0
30	Et	Me	13.7
31	Et	n-Pr	4.8




Compound	X	R	IC ₅₀ ^a
Sildenafil	-	-	3.9
25	Br	n-Pr	7.2
36	Br	Et	8.5
37	Br	n-Bu	41
38	Br	n-Hex	58
24	Cl	n-Pr	6.6
39	Cl	Et	12.6

PDEs	IC ₅₀ (nM)	
	5	Sildenafil
PDE5A	1.6	3.9
PDE1	741	230
PDE2	>10000	>10000
PDE3	>10000	7310
PDE4	>10000	5830
PDE6C	45.6	39.2
PDE7A1	>10000	4690
PDE8A1	>10000	>10000
PDE9A2	>10000	>10000
PDE10A2	>10000	>10000
PDE11A4	3360	4210


Dose	route	CL	V	MRT _{0-10h}	AUC _{0-10h}	C _{max}	t _{1/2}	T _{max}	F
(mg/kg)		(L/h/kg)	(L/kg)	(h)	(ug/L*h)	(ug/L)	(h)	(h)	(%)
5	iv	1.17±0.35	2.07±0.13	0.81±0.44	4474±1147	-	1.29±0.35	-	-
10	oral	-	-	3.09±0.48	895±376	468±300	3.94±0.65	0.25 (0.25-0.5)	10.0



Discovery of monocyclic pyrimidinones as novel inhibitors of PDE5
167x106mm (300 x 300 DPI)




The synthesis of compounds with monocyclic pyrimidinone core
Reagents and conditions: (a) (i) HSO₃Cl, 0 °C; (ii) N-methyl piperazine, Et₃N, DCM, 0 °C; (b) LiHMDS, THF, room temp; (c) K₂CO₃, DMF, 100 °C; (d) Ethyl cyanoacetate, K₂CO₃, DMF, 100 °C; (e) Diethyl malonate, K₂CO₃, DMF, 100 °C; (f) Ac₂O, 80 °C; (g) Cl₂, Et₃N, DCM, 0 °C; or Br₂, Et₃N, DCM, 0 °C; or I₂, AgNO₃, MeOH, room temperature
165x176mm (300 x 300 DPI)



The synthesis of compounds 36-39


Reagents and conditions: (a) Hydroxylamine hydrochloride, K₂CO₃, Methanol, and water; (b) H₂ (3MPa) / Pd-C; (c) Ethyl isobutyrylacetate, K₂CO₃, DMF, 100°C; (d) Cl₂ (g), Et₃N, DCM, 0°C; or Br₂, Et₃N, DCM, 0°C; (e) (i) HSO₃Cl, 0°C; (ii) N-methyl piperazine, Et₃N, DCM, 0°C.

171x95mm (300 x 300 DPI)




A crucial water molecule in the crystal structures of PDE5 in complex with different inhibitors. The complex structures were superimposed by fitting all the C α atoms of the enzyme. (A) The H-bond interactions of the water molecule with sildenafil, side-chain residues, and the other water molecule in the complex structure of PDE5/sildenafil (pdb code 2H42). (B) Superimposition of compound 2 and sildenafil as well as the crucial water molecule. (C) Superimposition of inhibitors in five complex structures with pdb codes 1UDT (cyan), 2H42 (green), 1RKP (magenta), 3BJC (yellow), and 3B2R (wheat). The water molecules at the same location in these five complex structures as well as in the apo structure (pdb code 2H40, red) are shown as colored balls. SP1 and SP2 represent two sub-pockets that interact with substituents of the pyrazol, pyrrole or other heterocyclic rings of the inhibitors. (D) Superimposition of compound 5 with sildenafil as well as the key water molecule.

127x101mm (300 x 300 DPI)




The interactions between two compounds (2 and 5) and PDE5 in crystal structures of their complexes. (A, B) LIGPLOT representations of the interactions of compounds 2 (A) and 5 (B) with the enzyme. (C, D) Molecular surface of the binding pockets for compounds 2 (C) and 5 (D) in their complex structures with the PDE5 catalytic domain. The crucial water molecule is shown as a red ball and the H-bonds formed between it and the residues are labeled with black dash lines.

84x81mm (300 x 300 DPI)



Mean plasma concentrations of compound 5 in male rat, after single p.o. 10 mg/kg (◆) & i.v 5 mg/kg (●). Data used to generate the profile are the Mean±SD from three male rats (individual samples at all time points). 174x129mm (89 x 89 DPI)



Effect of compound 5 on ICP/BP 30 min after p.o. administration (10 mg/kg) in the rat erection model. Data are expressed as Mean $\pm$ SD (n=3). Percentage increase: ((ICP/BP)after-(ICP/BP)before) / ((ICP/BP)before100%, *: compared with vehicle $P < 0.05$, student's t-test. 84x58mm (150 x 150 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Table of Contents
84x84mm (300 x 300 DPI)